- -

Radioactive iodine and female fertility

RiuNet: Repositorio Institucional de la Universidad Politécnica de Valencia

Compartir/Enviar a

Citas

Estadísticas

  • Estadisticas de Uso

Radioactive iodine and female fertility

Mostrar el registro completo del ítem

Navarro, P.; Rocher, S.; Miró Martínez, P.; Oltra Crespo, S. (2022). Radioactive iodine and female fertility. Scientific Reports. 12(1):1-7. https://doi.org/10.1038/s41598-022-07592-8

Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10251/194513

Ficheros en el ítem

Thumbnail
Nombre: NavarroRocherMiro ...
Tamaño: 1023.Kb
Formato: PDF
Descripción: Versión editorial
Abrir/Preview

Metadatos del ítem

Título: Radioactive iodine and female fertility
Autor: Navarro, Pino Rocher, Sandra Miró Martínez, Pau Oltra Crespo, Sandra
Entidad UPV: Universitat Politècnica de València. Escuela Politécnica Superior de Alcoy - Escola Politècnica Superior d'Alcoi
Fecha difusión:
Resumen:
[EN] Radioactive iodine (I-131) is used after surgery in the treatment of Differentiated Thyroid Carcinoma (DTC). There is no solid evidence about the potential deleterious effect of I-131 on women fertility. The objective ...[+]
Derechos de uso: Reconocimiento (by)
Fuente:
Scientific Reports. (issn: 2045-2322 )
DOI: 10.1038/s41598-022-07592-8
Editorial:
Nature Publishing Group
Versión del editor: https://doi.org/10.1038/s41598-022-07592-8
Coste APC: 2165,9 €
Tipo: Artículo

References

Rego-Iraeta, A., Pérez-Méndez, L. F., Mantinan, B. & Garcia-Mayor, R. V. Time trends for thyroid cancer in northwestern Spain: True rise in the incidence of micro and larger forms of papillary thyroid carcinoma. Thyroid 19(4), 333–340. https://doi.org/10.1089/thy.2008.0210 (2009).

Tuttle, R. M. et al. Controversies, consensus, and collaboration in the use of 131I therapy in differentiated thyroid cancer: A joint statement from the American thyroid association, the European association of nuclear medicine, the society of nuclear medicine and molecular imaging, and the European thyroid association. Thyroid 29(4), 461–470. https://doi.org/10.1089/thy.2018.0597 (2019).

Pacini, F. et al. Italian consensus on diagnosis and treatment of differentiated thyroid cancer: Joint statements of six Italian societies. J. Endocrinol. Invest. 41(7), 849–876. https://doi.org/10.1007/s40618-018-0884-2 (2018). [+]
Rego-Iraeta, A., Pérez-Méndez, L. F., Mantinan, B. & Garcia-Mayor, R. V. Time trends for thyroid cancer in northwestern Spain: True rise in the incidence of micro and larger forms of papillary thyroid carcinoma. Thyroid 19(4), 333–340. https://doi.org/10.1089/thy.2008.0210 (2009).

Tuttle, R. M. et al. Controversies, consensus, and collaboration in the use of 131I therapy in differentiated thyroid cancer: A joint statement from the American thyroid association, the European association of nuclear medicine, the society of nuclear medicine and molecular imaging, and the European thyroid association. Thyroid 29(4), 461–470. https://doi.org/10.1089/thy.2018.0597 (2019).

Pacini, F. et al. Italian consensus on diagnosis and treatment of differentiated thyroid cancer: Joint statements of six Italian societies. J. Endocrinol. Invest. 41(7), 849–876. https://doi.org/10.1007/s40618-018-0884-2 (2018).

Lee, S. L. Complications of radioactive iodine treatment of thyroid carcinoma. J. Natl. Compr. Canc. Netw. 8(11), 1277–1287. https://doi.org/10.6004/jnccn.2010.0094 (2010).

Clement, S. C. et al. Intermediate and long-term adverse effects of radioiodine therapy for differentiated thyroid carcinoma–a systematic review. Cancer Treat Rev. 41(10), 925–934. https://doi.org/10.1016/j.ctrv.2015.09.001 (2015).

Andresen, N. S. et al. Radioiodine ablation following thyroidectomy for differentiated thyroid cancer: Literature review of utility, dose, and toxicity. Eur. Thyroid J. 6(4), 187–196. https://doi.org/10.1159/000468927 (2017).

Pacini, F. et al. Testicular function in patients with differentiated thyroid carcinoma treated with radioiodine. J. Nucl. Med. 35(9), 1418–1422 (1994).

Wichers, M. et al. Testicular function after radioiodine therapy for thyroid carcinoma. Eur. J. Nucl. Med. 27(5), 503–507. https://doi.org/10.1007/s002590050535 (2000).

Raymond, J. P. et al. Temporary ovarian failure in thyroid cancer patients after thyroid remnant ablation with radioactive iodine. J. Clin. Endocrinol. Metab. 69(1), 186–190. https://doi.org/10.1210/jcem-69-1-186 (1989).

Souza Rosário, P. W. et al. Ovarian function after radioiodine therapy in patients with thyroid cancer. Exp. Clin. Endocrinol. Diabetes. 113(6), 331–333. https://doi.org/10.1055/s-2005-837666 (2005).

Sioka, C., Kouraklis, G., Zafirakis, A., Manetou, A. & Dimakopoulos, N. Menstrual cycle disorders after therapy with iodine-131. Fertil. Steril. 86(3), 625–628. https://doi.org/10.1016/j.fertnstert.2006.02.081 (2006).

Sawka, A. M. et al. A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors. Clin. Endocrinol. (Oxf). 69(3), 479–490. https://doi.org/10.1111/j.1365-2265.2008.03222.x (2008).

Ceccarelli, C., Bencivelli, W., Morciano, D., Pinchera, A. & Pacini, F. 131I therapy for differentiated thyroid cancer leads to an earlier onset of menopause: Results of a retrospective study. J. Clin. Endocrinol. Metab. 86(8), 3512–3515. https://doi.org/10.1210/jcem.86.8.7719 (2001).

Wu, J. X. et al. Reproductive outcomes and nononcologic complications after radioactive iodine ablation for well-differentiated thyroid cancer. Thyroid 25(1), 133–138. https://doi.org/10.1089/thy.2014.0343 (2015).

Dewailly, D. et al. The physiology and clinical utility of anti-Mullerian hormone in women [published correction appears in Hum Reprod Update. Sep-Oct;20(5):804]. Hum. Reprod. Update. 20(3), 370–385. https://doi.org/10.1093/humupd/dmt062 (2014).

Tal, R. & Seifer, D. B. Ovarian reserve testing: A user’s guide. Am. J. Obstet. Gynecol. 217(2), 129–140. https://doi.org/10.1016/j.ajog.2017.02.027 (2017).

La Marca, A. et al. Normal serum anti-Müllerian hormone levels in the general female population and the relationship with reproductive history. Eur. J. Obstet. Gynecol. Reprod. Biol. 163(2), 180–184. https://doi.org/10.1016/j.ejogrb.2012.04.013 (2012).

Acıbucu, F., Acıbucu, D. O., Akkar, Ö. B. & Dokmetas, H. S. Evaluation of ovarian reserve with AMH level in patients with well-differentiated thyroid cancer receiving radioactive iodine ablation treatment. Exp. Clin. Endocrinol. Diabetes. 124(10), 593–596. https://doi.org/10.1055/s-0042-115639 (2016).

Giusti, M. et al. Anti-Müllerian hormone in premenopausal females after ablative radioiodine treatment for differentiated thyroid cancer. Endocrine 60(3), 516–523. https://doi.org/10.1007/s12020-017-1510-3 (2018).

Yaish, I. et al. A single radioactive iodine treatment has a deleterious effect on ovarian reserve in women with thyroid cancer: Results of a prospective pilot study. Thyroid 28(4), 522–527. https://doi.org/10.1089/thy.2017.0442 (2018).

Evranos, B. et al. Effects of radioactive iodine therapy on ovarian reserve: A prospective pilot study. Thyroid 28(12), 1702–1707. https://doi.org/10.1089/thy.2018.0129 (2018).

van Velsen, E. F. S. et al. Longitudinal analysis of the effect of radioiodine therapy on Ovarian reserve in females with differentiated thyroid cancer. Thyroid 30(4), 580–587. https://doi.org/10.1089/thy.2019.0504 (2020).

Whitcomb, B. W. et al. Menstrual cycle characteristics in adolescence and early adulthood are associated with risk of early natural menopause. J. Clin. Endocrinol. Metab. 103(10), 3909–3918. https://doi.org/10.1210/jc.2018-01110 (2018).

Navarro, P., Fajardo, C. & Giner, V. Buenas prácticas en Diabetes y Embarazo (Universidad Internacional Menéndez Pelayo, 2018).

de Kat, A. C. et al. Back to the basics of ovarian aging: A population-based study on longitudinal anti-Müllerian hormone decline. BMC Med. 14(1), 151. https://doi.org/10.1186/s12916-016-0699-y (2016).

Ethics Committee of the American Society for Reproductive Medicine. Electronic address: ASRM@asrm.org. Fertility preservation and reproduction in patients facing gonadotoxic therapies: An Ethics Committee opinion. Fertil. Steril. 110(3):380–386. https://doi.org/10.1016/j.fertnstert.2018.05.034 (2018).

Oktay, K. et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J. Clin. Oncol. 36(19), 1994–2001. https://doi.org/10.1200/JCO.2018.78.1914 (2018).

[-]

recommendations

 

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro completo del ítem